233 related articles for article (PubMed ID: 33558714)
1. Urological cancer patients receiving treatment during COVID-19: a single-centre perspective.
Williams ST; El Badri S; Hussain SA
Br J Cancer; 2021 Apr; 124(9):1513-1515. PubMed ID: 33558714
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
4. Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes.
Mian BM; Siddiqui S; Ahmad AE
Urol Oncol; 2021 May; 39(5):258-267. PubMed ID: 33129674
[TBL] [Abstract][Full Text] [Related]
5. Referral pattern for urologic malignancies before and during the COVID-19 pandemic.
Maganty A; Yu M; Anyaeche VI; Zhu T; Hay JM; Davies BJ; Yabes JG; Jacobs BL
Urol Oncol; 2021 May; 39(5):268-276. PubMed ID: 33308974
[TBL] [Abstract][Full Text] [Related]
6. Delaying Cancer Cases in Urology during COVID-19: Review of the Literature.
Tachibana I; Ferguson EL; Mahenthiran A; Natarajan JP; Masterson TA; Bahler CD; Sundaram CP
J Urol; 2020 Nov; 204(5):926-933. PubMed ID: 32692934
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19.
So ACP; Karampera C; Khan M; Russell B; Moss C; Monroy-Iglesias MJ; Thillai K; Josephs DH; Pintus E; Rudman S; Van Hemelrijck M; Dolly S; Enting D
BMC Urol; 2022 Apr; 22(1):71. PubMed ID: 35488333
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome.
Girmenia C; Gentile G; Micozzi A; Petrucci L; Malaspina F; Di Prima A; Baldacci E; Bianchi S; Pugliese P; Turriziani O; Antonelli G; Tombolini V; Foà R; Martelli M
Acta Haematol; 2020; 143(6):574-582. PubMed ID: 32932252
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
Rüthrich MM; Giessen-Jung C; Borgmann S; Classen AY; Dolff S; Grüner B; Hanses F; Isberner N; Köhler P; Lanznaster J; Merle U; Nadalin S; Piepel C; Schneider J; Schons M; Strauss R; Tometten L; Vehreschild JJ; von Lilienfeld-Toal M; Beutel G; Wille K;
Ann Hematol; 2021 Feb; 100(2):383-393. PubMed ID: 33159569
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Lièvre A; Turpin A; Ray-Coquard I; Le Malicot K; Thariat J; Ahle G; Neuzillet C; Paoletti X; Bouché O; Aldabbagh K; Michel P; Debieuvre D; Canellas A; Wislez M; Laurent L; Mabro M; Colle R; Hardy-Bessard AC; Mansi L; Colomba E; Bourhis J; Gorphe P; Pointreau Y; Idbaih A; Ursu R; Di Stefano AL; Zalcman G; Aparicio T;
Eur J Cancer; 2020 Dec; 141():62-81. PubMed ID: 33129039
[TBL] [Abstract][Full Text] [Related]
12. [Palliative care of tumors of the excretory urinary tract].
Grise P; Hacpille L
Rev Prat; 1997 Feb; 47(4):402-9. PubMed ID: 9114527
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of asymptomatic COVID-19 infection in cancer patients. A cross-sectional study at a tertiary cancer center in New York City.
Ibrahim M; Natarajan V; Murthy P; Meghal T; Xu Y; Wiesel O
Cancer Treat Res Commun; 2021; 27():100346. PubMed ID: 33756172
[TBL] [Abstract][Full Text] [Related]
14. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
15. Lessons from the coronavirus disease 2019 pandemic: Will virtual patient management reshape uro-oncology in Germany?
Rodler S; Apfelbeck M; Stief C; Heinemann V; Casuscelli J
Eur J Cancer; 2020 Jun; 132():136-140. PubMed ID: 32361628
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
17. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania.
Trifanescu OG; Gales L; Bacinschi X; Serbanescu L; Georgescu M; Sandu A; Michire A; Anghel R
In Vivo; 2022; 36(2):934-941. PubMed ID: 35241552
[TBL] [Abstract][Full Text] [Related]
19. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.
Martinez Chanza N; Werner L; Plimack E; Yu EY; Alva AS; Crabb SJ; Powles T; Rosenberg JE; Baniel J; Vaishampayan UN; Berthold DR; Ladoire S; Hussain SA; Milowsky MI; Agarwal N; Necchi A; Pal SK; Sternberg CN; Bellmunt J; Galsky MD; Harshman LC;
Eur Urol Oncol; 2020 Oct; 3(5):671-679. PubMed ID: 31411990
[TBL] [Abstract][Full Text] [Related]
20. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience.
Madhusoodhan PP; Pierro J; Musante J; Kothari P; Gampel B; Appel B; Levy A; Tal A; Hogan L; Sharma A; Feinberg S; Kahn A; Pinchinat A; Bhatla T; Glasser CL; Satwani P; Raetz EA; Onel K; Carroll WL
Pediatr Blood Cancer; 2021 Mar; 68(3):e28843. PubMed ID: 33338306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
